SEREFHANOĞLU, Songul Hacettepe University Hospital - Department of Internal Medicine, Division of Hematology, turkey , BÜYÜKASIK, Yahya Hacettepe University Hospital - Department of Internal Medicine, Division of Hematology, turkey , AKSU, Salih Hacettepe University Hospital - Department of Internal Medicine, Division of Hematology, turkey , GÖKER, Hakan Hacettepe University Hospital - Department of Internal Medicine, Division of Hematology, turkey , SAYINALP, Nilgun Hacettepe University Hospital - Department of Internal Medicine, Division of Hematology, turkey , ÇETĠNER, Deniz Hacettepe University Hospital - Department of Internal Medicine, Division of Hematology, turkey , HAZNEDAROĞLU, Ibrahim Celalettin Hacettepe University Hospital - Department of Internal Medicine, Division of Hematology, TURKEY , ÖZCEBE, Osman Ilhami Hacettepe University Hospital - Department of Internal Medicine, Division of Hematology, turkey

DISEASE CHARACTERISTICS AND FACTORS INFLUENCING TREATMENT RESPONSE IN NEWLY DIAGNOSED ACUTE MYELOBLASTIC LEUKEMIA PATIENTS: A SINGLE CENTER EXPERIENCE

25891

Objective: Generally, patients who have no important co-morbidities are evaluated in acute leukemia studies. Because of this reason, the treatment results in literature may be incompatible with real life. Materials and methods: Data of 147 newly diagnosed adult AML patients followed in our institute between January 2003 and December 2008 were retrospectively reviewed. Median age was 48 (range 16-85) and, 11(7.5%) had Core-Binding-Factor (CBF) AML, 18(12.2%) had Acute Promyelocytic AML (APL) and 118 (80.3%) had other AML. The 74.8% of patients received idarubicine+cytarabine (3+7), 13.6% received mitoxantrone+cytarabine (3+7), 2.9% received high dose cytarabine+mitoxantrone, 0.9% received cytarabine, 0.9% received mitoxantrone+cytarabine+etoposide, 1.9% received idarubicine+cytarabine (2+5) and 4.8% received AIDA protocols.Results: The mean hemoglobin, white blood cell and platelet counts were 8.6 g/dl (3.5-14), 41 359/mm3 (600-300.000) and 64 086/mm3 (3000–459.000), respectively. 12 (8.1%) of the patients received allogeneic stem cell transplantation. The response rates in patients after the induction regimens: 52.4% achieved complete remission (CR), 27.2% died during induction (induction mortality) and 5.4% had resistant disease. The OS rate at 5.9 years was 29%. DFS rate at 5 years was 44% in patients of remission obtained with induction. Conclusion: In univariate analysis, age and ECOG performance status were associated with complete response. The age (≤30 32%, 30-59 37%, ≥60 13%, p= 0.003), ECOG performance status (ECOG≤1 33%, ECOG 1 17%, p= 0.001) and AML karyotype (CBF AML 72%, APL 41%, other AML 24%, p= 0.043) were associated with overall survival. In multivariate analysis, only ECOG performance status (p=0.003) was found associated with overall survival.

74

Adult acute myeloblastic leukemia , overall survival , disease , free survival

Journal Of Istanbul Faculty Of Medicine

79